Amgen (AMGN)$339.30

Market Cap: 150.59 BCurrency: USD

Research Snapshot

Static fundamentals, valuation context, and investor signals for Amgen (AMGN).

HEALTHCARE

DRUG MANUFACTURERS - GENERAL

DCF ready

Valuation

24.2x

EV/FCF, 4.1% FCF yield

Quality

12.2%

ROIC, 22.0% FCF margin

Growth

7.6%

5Y sales (revenue) CAGR

Balance sheet

6.3x

Debt/equity, 1.1x current ratio

Superinvestors

Top: David Katz (3.2%)

Strengths to research

Return on equity is strong at 89.1%.
Free cash flow margin is healthy at 22.0%.
4 tracked superinvestors report a position.
10 annual periods are available for trend analysis.

Watchouts

Debt/equity is high at 6.3x.

Annual data: 10 periods

Quarterly data: 24 periods

Stock snapshot: May 25, 2026

Static dataset: May 25, 2026

Quality Scorecard

Build-time composite score for AMGN.

Grade C

/ 100

Compare to:

LLY JNJ UNH ABBV NVO

Peer Comparison

Target stock against 8 market-cap comparable peers.

Heat map: red worst to green best


AMGN Target	Amgen	$150.6B	23.8x	24.2x	12.2%	7.6%	22.0%	N/A	3.2x	N/A
PFE	Pfizer Inc.	$135.4B	19.0x	14.8x	9.0%	8.5%	14.5%	N/A	N/A	N/A
SNY	Sanofi Aventis	$133.3B	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GILD	Gilead Sciences	$128.0B	19.8x	15.4x	17.9%	3.6%	32.1%	N/A	1.7x	N/A
MRK	Merck & Co.	$208.5B	16.8x	15.7x	34.7%	9.4%	19.0%	N/A	N/A	N/A
BMY	Bristol-Myers Squibb	$101.9B	17.2x	10.6x	11.1%	2.5%	26.7%	N/A	N/A	N/A
NVS	Novartis AG	$223.3B	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RHHVF	Roche Holdings AG DIV RT	$263.8B	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RHHBY	Roche Holding AG ADR	$265.2B	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Financial Charts

No financial data available for AMGN (annual).

4 superinvestors own AMGN

Current quarter ownership and quarter-over-quarter share changes.

Superinvestor ownership

Fund	Shares	Value	% Portfolio	QoQ Change
David Katz Matrix Asset Advisors	99,810	$35M	3.22%	0.0%
Torray Funds Torray Funds	54,012	$19M	2.98%	0.0%
Dodge & Cox Dodge & Cox	13,367	$5M	0.00%	0.0%
Mairs & Power Growth Fund Mairs & Power Growth Fund	4,964	$2M	0.02%	0.0%